摘要
目的探讨重组人白介素-11雾化吸入对头颈部肿瘤患者放射性咽喉炎的疗效。方法选取161例初诊头颈部肿瘤患者，在知情同意原则下以区组随机化分组原则分为观察组87例，对照组74例。观察组在照射剂量达20Gy时使用重组人白介素-11雾化吸入至放疗结束，对照组在出现放射性咽喉炎时进行常规治疗。采用RTOG标准分别观察2组患者放射性咽喉炎发生和治疗情况。结果观察组比对照组放射性咽喉炎出现的平均时间滞后、严重程度降低、治愈时间缩短，差异均有统计学意义。结论重组人白介素-11雾化吸入可防治放射性咽喉炎，效果优于常规治疗，值得进一步研究并临床推广应用。
Objective To conduct prospective randomized controlled clinical observation on patients with nasopharyngeal carcinoma under chemotherapy and radiotherapy using inhaling therapy with recombinant human interleukin 11, and the preventing and curing effect of recombinant human interleukin 11 on radiationinduced pharyngitis is evaluated. Methods 161 cases of newly diagnosed patients with head and neck cancer were selected under the principle of informed consent and these 161 cases were di- vided into the observation group （87 cases） and the control group （74 cases） based on randomization principle. In the observation group, when the dose reached 20Gy, then recombinant human interleukin-11 inhaling therapy was applied till the end of radiotherapy, for the control group, conventional treatment was applied in the event of radioactive throat. RTOG criteria were used during the observation in patients with the occur- rence and treatment of radioactive pharyngitis. Results When compared with the control group, the average time for radioactivity to appear was prolonged, the severity decreased and the healing time was shortened in the observation group, those data were statistically significant. Conclusions Recombinant human interleukin- 11 inhaling therapy can prevent and cure inhalation of radioactive pharyngitis and this therapy is better than conventional treatment. It＇s worthy of further study and clinical application.
出处
《中国实用护理杂志》
北大核心
2014年第21期6-8,共3页
Chinese Journal of Practical Nursing
基金
基金项目：四川省教育厅项目（10SA145）
南充市科技局项目（2010SF20）
关键词
注射用重组人白介素-11
雾化吸入
放射性咽喉炎
Recombinant human interleukin- 11 for injection
Inhaling therapy
Radioactivepharyngitis
